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ABSTRACT
In a previous study, the gene EgP450 that encodes the proteins of 505 amino acids was isolated from oil palm. The 
recombinant protein EgP450 is bound to phenylurea-like herbicides which detoxify the substance. Aflatoxin B1 (AFB1), 
a mycotoxin produced by Aspergillus sp., is another toxic compound that is known to cause acute toxic effects and act 
as a hepatocarcinogenic agent. This study aimed to examine the role of EgP450 enzyme in mycotoxin bioactivation in 
human mesenchymal stem cells (hMSCs). Docking analysis showed that EgP450 is bound to the group of carcinogens, 
which includes AFB1, n-(2-fluorenyl) acetamide, n-n-butyl-n-butan-4-ol-nitrosamine, n-nitrosodiethylamine, 
n-nitrosodiethylamine and n-nitrosodimethylamine. An in vivo aflatoxin toxicity test on hMSCs and AFB1 induces the 
expression of Bmi-1 which is one of the markers for the development of cancer. The presence of EgP450 at 0.15 µg/mL 
could reduced the Bmi-1 expression in AFB1 induced cells. Moreover, this protein also showed some antioxidant activity. 
These results exhibited the enormous potential of EgP450 in the detoxification processes.
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ABSTRAK
Dalam kajian sebelum ini, gen EgP450 yang mengekod 505 protein asid amino telah dipencilkan daripada kelapa sawit. 
Protein rekombinan EgP450 terikat kepada racun herba seperti phenylurea yang menyahtoksin bahan. Aflatoksin B1 
(AFB
1
), mikotoksin yang dihasilkan oleh Aspergillus sp., adalah satu lagi toksik sebatian yang diketahui menyebabkan 
kesan toksik akut dan bertindak sebagai agen hepatokarsinogen. Kajian ini bertujuan untuk meneliti peranan enzim 
EgP450 dalam biopengaktifan mikotoksin sel stem mesenkim manusia (hMSCs). Analisis dok menunjukkan bahawa 
EgP450 terikat kepada kumpulan karsinogen, termasuk AFB
1
, n-(2-fluorenil) asetamid, n-n-butil-n-butan-4-ol-
nitrosamin, n-nitrosodietilamin, n-nitrosodietilamin dan n-nitrosodimetilamin. Ujian in vivo ketoksikan aflatoksin 
ke atas hMSCs dan AFB
1
 mengaruh ekspresi Bmi-1 yang merupakan salah satu penanda bagi pembangunan kanser. 
Kehadiran EgP450 pada 0.15 µg/mL boleh mengurangkan ekspresi Bmi-1 dalam sel aruhan AFB
1
. Selain itu, protein 
ini juga menunjukkan beberapa aktiviti antioksidan. Keputusan ini menunjukkan potensi besar EgP450 dalam proses 
penyahtoksikan. 
Kata kunci: Karsinogen; penyahtoksikan; sitokrom P450  monooksigenase
INTRODUCTION
Aflatoxins form a major group of mycotoxin. They 
occur in a wide range of human foodstuffs and can cause 
hepatocarcinogenesis in animals (Groopman et al. 1988; 
Portman et al. 1970; Vesselinovitch et al. 1972; Wogan 
1973). In addition, epidemiological studies showed that 
humans are possibly susceptible to aflatoxin induced 
hepatocarcinogenesis (Bulatao-Jayme et al. 1982; 
Groopman et al. 1988; Peers & Linsell 1973; Peers et 
al. 1987). Aflatoxin B1 (AFB1) is thought to be the most 
carcinogenic aflatoxin. It requires the oxidation of the 8, 
9 double bond of AFB1 in order to yield the biologically 
active AFB1-8,9-epoxide. AFB1-8,9-epoxide in turn 
can react with DNA, whereas, microsomal cytochrome 
P450 (CYP)-mediated AFB1 oxidation produces various 
hydroxylated metabolites such as aflatoxin Ml (AFM1), 
aflatoxin Pl (AFP1) and aflatoxin Q1, (AFQ1). These are 
much less toxic than the original aflatoxins. In human 
liver microsomes, AFM1 and AFQ1 are the main oxidative 
detoxification products of AFB1 (Ramsdell et al. 1991; 
Raney et al. 1992).
 P450s are widespread in nature, i.e. they can be 
found in all organisms. P450 enzymes that metabolize 
xenobiotics play a key role in the oxidative metabolism 
of a wide range of exogenous as well as endogenous 
compounds including plant toxins, environmental 
carcinogens and a wide variety of anticancer drugs. P450 
enzymes in human liver are, in the first place, responsible 
for the activation of AFB1 to AFB1-8,9-epoxide which is 
electrophilic. Several studies reported that there are five 
distinct human liver P450s, including 1A2, 2A6, 2B7, 
3A3, 3A4 and 2A13 that can activate AFB1 to mutagenic 
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metabolites and derivatives bound to DNA (Aoyama et al. 
1990; He et al. 2006; Kensler et al. 2011). In the human 
liver, microsomes CYP3A4 is the most important P450 
enzyme involved in the activation of AFB1 to genotoxic 
AFB1-8,9-epoxide or to the nontoxic 3α-hydroxy AFB1 (Shimada et al. 1989). It has been suggested that human 
CYP1A2 is the P450 with high affinity that is responsible 
for the bioactivation of AFB1 at low concentrations which is comparable to high concentrations in the human diet 
(Crespi et al. 1991). Additional data are also congruent with 
the hypothesis that in human liver microsomes, CYP1A2 is 
the main P450 involved in the oxidation of AFB1 to AFM1, whereas, CYP3A4 is the predominant P450 responsible for 
the conversion of AFB1 to AFQ1 (Gallagher et al. 1996, 1994; Guengerich et al. 1998).
 Previously, EgP450 was demonstrated as the most 
efficient oil palm CYP enzyme that can protect rice seedlings 
from exogenous herbicides of the phenylurea family. The 
present study aimed to characterize the role of EgP450 
enzyme in AFB1 bioactivation in human stem cells which 
leads to the activation or detoxification of AFB1.
MATERIALS AND METHODS
MOLECULAR DOCKING SIMULATIONS AND 
INTERACTION ANALYSIS
The molecular interactions docking was used for screening 
the EgP450 with various chemicals and carcinogens using 
the AutoDOCK simulation tool, whereas, the EgP450 is 
the receptor protein and set of the substrates are ligand 
molecules (Huey et al. 2007; Morris et al. 1996) and the 
SLITHER server (Lee et al. 2009).
PREPARATION AND PURIFICATION OF 
RECOMBINANT EGP450
The recombinant protein was prepared from Escherichia 
coli BL21 (DE3) harbouring EgP450 according to the 
method previously described (Phongdara et al. 2012).
CULTURE OF HMSCS AND AFB1 TREATMENT
hMSCs were cultured on medium containing mesenchymal 
stem cell growth medium (Biomed Diacnostic, Thailand) 
supplemented with supplement mix mesenchymal stem 
cell growth medium. Then 1% of penicillin/streptomycin 
(Biochrom, Berlin, Germany) was put into the culture 
which was continued in the first culture for 48 h. The 
culture was maintained at 5% CO2 under the humidifier at 
37°C. To determine a cytotoxic concentration of AFB1, the stem cells were treated with chemical at concentrations 
of AFB1 0 mg/mL and 0.0625 mg/mL for 24 h. In order 
to evaluate P450 effects (0.15, 0.30 and 0.60 μg/mL, 
respectively), after plating the toxin, the culture medium 
was mixed at the appropriate concentrations. After 24 
h, culture sera was collected after the toxin treatment. 
Cytotoxicity was evaluated by real-time quantitative 
polymerase chain reaction.
BMI-1 mRNA EXPRESSION IN STEM CELLS
B-cell-specific moloney murine leukemia virus integration 
site 1 (Bmi-1), is a prognostic marker in many cancers 
(Mihara et al. 2006; Song et al. 2006). Bmi-1 expression 
levels were quantified in cultured cells of the hMSCs by real-
time quantitative polymerase chain reaction. The mRNA 
levels were standardized using glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as a reference housekeeping gene. 
The data were analyzed using 2-rrCT method normalized 
with GAPDH (Livak & Schmittgen 2001).
MEASURING OF ANTIOXIDANT ACTIVITY OF EgP450 BY 
CHEMILUMINESCENCE : XANTHINE - 
XANTHINE OXIDASE SYSTEM
The xanthine oxidase inhibition assay was measured 
spectrophotometrically by using the procedure of Vieira 
et al. (2009). Antioxidant activity assay was calculated 
using the formula:
Antioxidant activity 
= 1 – [(Sample(P) – Sample(N))/(Positive control) 
 – (Negative control)].
RESULTS AND DISCUSSION
MOLECULAR DOCKING SIMULATIONS AND 
INTERACTION ANALYSIS
The docking results clearly show that EgP450 binds to 
carcinogens such as AFB1, n-(2-fluorenyl) acetamide (2-AAF), n-n-butyl-n-butan-4-ol-nitrosamine (BBN) 
n-nitrosodiethylamine (DEN) and n-nitrosodimethylamine 
(DMN) (Figure 1). The lowest docking score of EgP450/
AFB1 interaction model gave the best docking energy of 
-9.7 Kcal/mol (Table 1).
EXPRESSION AND PURIFICATION OF EgP450
The analysis of EgP450 enzyme of BL21 (DE3) cells on SDS-
PAGE obviously showed the target size of the recombinant 
protein fused to the histidine-tag and a 55-kDa molecular 
mass (Figure 2). The bacterial cells were lysed in a lysis 
buffer and purified by using affinity column. Most of 
the soluble recombinant P450 was bound to the column 
and eluted in the flow through in its denatured form and 
subsequently allowed to refold during cut-off column.
EFFECTS OF RECOMBINANT EGP450 PROTEIN 
ON STEM CELL IN VIVO
In order to see the effect of AFB1 on the stem cell hMSCs, 
cells were cultivated and treated with various concentrations 
to AFB1. Finally, the concentration of 0.0625 was chosen in 
this study. Several treatments which included EgP450 were 
designed to demonstrate the counter effect of the protein. 
Bmi-1 is a prognostic marker in many cancer development. 
The Bmi-1 expression interacts with several signaling 
containing Wnt, Akt, Notch, Hedgehog and receptor 
tyrosine kinase (RTK) pathway. Here, we develop a method 
  1501
to screen a potential toxic and detoxification substances by 
measuring the expression level of Bmi-1.
 Figure 3 demonstrates the increase of Bmi-1 
expression in hMSCs treated with AFB1 when compared 
with the control (without AFB1), whereas, the expression 
of Bmi-1 is low or near normal when included at low 
concentration of EgP450 together with AFB1. However, at 
the high concentration of EgP450 (0.30 and 0.60 μg/mL), 
EgP450 helped AFB1 to enhance the Bmi-1 expression. 
FIGURE 1. Molecular interaction models of EgP450 and carcinogens. The binding of EgP450 
to the AFB1 (A), n-(2-fluorenyl) acetamide (B), n-n-butyl-n-butan-4-ol-nitrosamine (C), 
n-nitrosodiethylamine (D) and n-nitrosodimethylamine (E)
TABLE 1. Energy table of EgP450 and carcinogens 
interaction simulations
Chemical Name Affinity (Kcal/Mol)
Aflatoxin B1 (AFB1)
N-(2-fluorenyl) acetamide (2-AAF)
N-N-butyl-N-butan-4-ol-nitrosamine (BBN)
N-nitrosodiethylamine (DEN)
N-nitrosodimethylamine (DMN)
-8.9 – -9.7
-7.9 – -8.0
-4.5 – -5.1
-4.0 – -4.0
-3.3 – -3.5
*The arrow indicates the recombinant protein
FIGURE 2. Purification of EgP450 as visualized on SDS-PAGE. 
The overexpressed protein is visible at 55 kDa after induction 
with IPTG. Lane 1: cell extracts, lane 2: lysis cell, lane 3: 
fraction after washing, lane 4-6: enzyme purification, 
lane M: standard of molecular weight
These data suggest that the EgP450 protein is involved 
in both the metabolic activation and the detoxification of 
AFB1. Therefore, it is recommended to use the appropriate 
low concentration of EgP450 in the treatment.
P450 ENZYME ANTIOXIDANT ACTIVITY
The ability of the enzyme was evaluated by Xanthine/2-
methyl-6-p-methoxyphenylethynyl-imidazopyrazinone 
(MPEC)/xanthine oxidase (XOD) assay. The inhibition of 
luminescent emission caused by the decrease of superoxide 
anions was measured using a luminometer. Counting 
of photons per minute and inhibition percentage of 
luminescence of the samples are shown in Table 2.
 The inhibition percentage of EgP450 at high 
concentration (50 μg/mL) was superior when compared 
to lower concentration (20 and 35 μg/mL). However, the 
activity is not high when compared to the control Vitamin C.
CONCLUSION
A molecular docking analysis showed that EgP450 
specifically binds to carcinogens, AFB 1,  n-(2-
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fluorenyl) acetamide (2-AAF), n-n-butyl-n-butane-4-
ol-nitrosamine (BBN) n-nitrosodiethylamine (DEN) and 
n-nitrosodimethylamine (DMN). This is the first time a 
stem cell hMSCs was used to study the genotoxic of 
AFB1 and its potential inhibitory effector, EgP450. The 
study provides a screening method and showed that low 
concentration of EgP450 possesses metabolic activity 
against the carciogenic effect of AFB1.
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